Trimetazidine

Drug Profile

Trimetazidine

Alternative Names: Adexor; Flavedon; Idaptan; Preductal; S 5016; Trimetazine; Vastarel; Vastarel F; Vastinan

Latest Information Update: 18 Jul 2014

Price : $50

At a glance

  • Originator Servier
  • Class Anti-ischaemics; Ischaemic heart disorder therapies; Piperazines; Small molecules; Vasodilators
  • Mechanism of Action Adenosine triphosphatase inhibitors; Antioxidants; Calcium channel antagonists; Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Angina pectoris; Eye disorders; Ischaemic heart disorders; Tinnitus; Vertigo

Most Recent Events

  • 19 Jun 2014 Dainippon Sumitomo Pharma is now called Sumitomo Dainippon Pharma
  • 22 Jun 2012 The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended that trimetazidine is not used for treatment of vertigo, tinnitus or vision disturbance, and the deletion of these indications from the marketing authorisation .
  • 01 Oct 2005 Sumitomo Pharmaceuticals has merged with Dainippon Pharmaceutical to form Dainippon Sumitomo Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top